On September 4, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer who develop an ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy. This marks the first FDA approval of a cancer therapy guided by detection of a resistance mutation in circulating tumor DNA (ctDNA) prior to radiographic disease progression.

Clinical Takeaway

✔ Camizestrant (Etcamah) plus a CDK4/6 inhibitor is now an FDA-approved option for HR+/HER2− locally advanced or metastatic breast cancer patients who develop an ESR1 mutation during aromatase inhibitor plus CDK4/6 inhibitor therapy, before imaging confirms disease progression.

✔ Approval was based on a clinically meaningful improvement in progression-free survival (16 months vs. 9.2 months) when switching to camizestrant plus CDK4/6 inhibitor versus continuing the aromatase inhibitor plus CDK4/6 inhibitor.

✔ ESR1 mutation detection using an FDA-authorized test is required to identify eligible patients; the FDA also authorized the Guardant360 CDx assay as a companion diagnostic, representing a new ctDNA-guided treatment paradigm in breast oncology.

✔ The FDA has required confirmatory studies to verify and describe clinical benefit because it remains uncertain whether intervention at ctDNA-detected ESR1 mutation, rather than at confirmed disease progression, translates into clinically meaningful benefit.

Drug Profile & Mechanism

  • Drug name: Etcamah (camizestrant)
  • Drug class: Oral selective estrogen receptor degrader (SERD) / next-generation endocrine therapy
  • Mechanism: Camizestrant is designed to overcome ESR1 mutation-driven endocrine resistance, a common acquired resistance mechanism that develops in HR-positive metastatic breast cancer following aromatase inhibitor (AI) therapy. ESR1 mutations alter the estrogen receptor, reducing the efficacy of standard AIs while remaining susceptible to SERD-class agents.
  • Route of administration: Oral tablet
  • Sponsor: AstraZeneca

Target Population

  • Indication: Adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer
  • Biomarker requirement: Detection of an ESR1 mutation during ongoing aromatase inhibitor and CDK4/6 inhibitor therapy, identified by an FDA-authorized test
  • Companion diagnostic: Guardant360 CDx assay — authorized to identify ESR1 mutations in circulating tumor DNA (ctDNA) from a blood-based liquid biopsy
  • ESR1 mutation prevalence context:
    • At initial diagnosis of HR-positive metastatic breast cancer: <5% of patients harbor ESR1 mutations
    • After disease progression on an aromatase inhibitor: ~40% of patients will have acquired ESR1 mutations

Safety

  • Boxed Warning: Risk of irregular heart rhythm (arrhythmia) when Etcamah is taken concomitantly with certain other medications
  • Warnings and Precautions:
    • Bradycardia (abnormally slow heart rate)
    • Embryo-fetal toxicity — potential harm to an unborn baby; patients of reproductive potential should be counseled accordingly
  • Full prescribing information, including the complete safety profile, will be available on Drugs@FDA

Key Clinical Implications

✔ ESR1 ctDNA detection during AI plus CDK4/6 inhibitor therapy is now clinically actionable, allowing eligible patients to switch therapy based on molecular resistance before radiographic progression occurs.

✔ Patient selection requires detection of an ESR1 mutation using an FDA-authorized test; Guardant360 CDx has been authorized as a companion diagnostic for identifying ESR1 mutations.

✔ All three approved CDK4/6 inhibitors (abemaciclib, palbociclib, ribociclib) are permitted in combination with camizestrant, offering flexibility in treatment sequencing based on patient history and tolerability.

✔ The cardiac safety profile warrants attention, including the boxed warning for irregular heart rhythm with certain concomitant medications and the warning/precaution for bradycardia.

✔ This approval establishes a new ctDNA-guided resistance-switching paradigm in breast oncology, which, if clinical benefit is verified in confirmatory studies, could shift standard practice toward proactive molecular monitoring and earlier therapeutic intervention.

Bottom Line

The accelerated approval of camizestrant (Etcamah) introduces the first treatment strategy guided by ctDNA-detected ESR1 resistance mutations before radiographic disease progression. The ~6.8-month improvement in median PFS over continued aromatase inhibitor-based therapy underscores the potential value of proactive molecular monitoring. Clinicians should be alert to the cardiac safety profile, ensure ESR1 mutation detection using an FDA-authorized test, and anticipate confirmatory studies that will verify and further describe the clinical benefit of this approach.

Sources: